Hydroxyzine revealing acquired neuromuscular weakness in a patient with COVID-19 disease

Abstract

Acquired neuromuscular weakness often develops in patients with an acute respiratory distress syndrome (ARDS), in particular in patients who are ventilated and sedated for long periods. This has been rarely described in the literature on ARDS secondary to SARS-CoV-2 infection. Our clinical case revealed the existence of these neuromuscular manifestations in the COVID-19 disease after the use of hydroxyzine, an antihistamine whose respiratory side-effects are unknown.

Keywords: Neuromuscular weakness, COVID-19, hydroxyzine, hypercapnia.

Downloads

Download data is not yet available.
Published
2021-07-01
How to Cite
Bahi, M., Aissaoui, Y., Belhadj, A., Qamouss, Y., & Seddiki, R. (2021). Hydroxyzine revealing acquired neuromuscular weakness in a patient with COVID-19 disease. The Southwest Respiratory and Critical Care Chronicles, 9(40), 74-76. https://doi.org/10.12746/swrccc.v9i40.875